Device Trial Radar · NCT07934914
Endovascular Brain-Computer Interface for Upper-Limb Paralysis
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
2
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Wei WuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nankai University
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests the safety and feasibility of a new type of brain-computer interface (BCI) in people with severe paralysis caused by stroke, spinal cord injury, or amyotrophic lateral sclerosis (ALS). A BCI records signals directly from the brain and uses them to control external devices. In this study, a small stent-shaped sensor (a metal mesh tube carrying tiny electrodes) is placed inside a vein on the surface of the brain through a needle puncture in a large vein below the collarbone, so no open-brain surgery is needed. Once in place, the sensor records brain activity while participants imagine or attempt movements. Two participants will be enrolled. One participant with stroke-related arm paralysis who still has rehabilitation potential will receive closed-loop functional electrical stimulation (FES): when the BCI detects the intention to move the paralyzed hand, electrical pulses are delivered to the arm muscles, producing real movement and sensory feedback. This pairing of intention and movement may help the brain rebuild damaged pathways. The other participant with ALS or severe paraplegia and no realistic chance of recovering voluntary movement will use the same sensor to control a robotic arm that helps perform daily tasks such as eating, grasping objects, and opening a door. For both participants, the study lasts about 60 days after sensor implantation. Training sessions last 45 minutes per day during weeks 2 to 4. Imaging (brain CT and CT venography), electroencephalography (EEG), blood tests, and movement or daily-living assessments are performed at regular intervals. After the week-4 evaluation, the sensor is either removed (short-term group) or left in place for continued monitoring (long-term group), based on the participant's own choice made before enrollment and on clinical judgment. The main measures are safety (side effects, blood clots, bleeding, device problems), quality of the recorded brain signals, accuracy of decoding movement intention, and improvement in arm function or daily-task performance.
Conditions
- Stroke
- Hemiplegia
- Spinal Cord Injury
- Paraplegia and Tetraplegia
- Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Interventions
Endovascular Venous BCI Type-A SensorDevice
A self-expanding nitinol stent (diameter 6 mm) carrying pure platinum electrodes, implanted under general anesthesia via the subclavian vein into the superior sagittal sinus or a cortical vein overlying the hand area of the motor cortex, using fusion of 3-dimensional venography with MRI for targeting. The sensor is connected to a chest-wall implanted relay and telemetry unit for wireless signal transmission.
BCI-Triggered Functional Electrical StimulationDevice
Closed-loop functional electrical stimulation of the paralyzed forearm muscles, triggered in real time by decoded movement intention. Daily 45-minute sessions during post-implantation weeks 2 to 4.
BCI-Controlled Bionic Robotic ArmDevice
A bionic robotic arm controlled by decoded movement intention, used to perform simulated daily tasks. Daily 45-minute training sessions during post-implantation weeks 2 to 4. Response latency, task success rate, and false trigger rate are recorded.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: From sensor implantation through post-implantation day 60
- Device Technical Success RateTime frame: Sensor implantation through post-implantation day 60
- Effective Signal Bandwidth of the Endovascular SensorTime frame: Each recording session from the first post-implantation recording through day 60
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.